摘要
目的综述药物肠淋巴转运的研究现状及研究进展,淋巴转运可避免肝脏首过效应,增加高亲脂性药物的口服生物利用度,对免疫抑制剂,抗肿瘤药物和抗感染药物具有重要的意义。方法系统检索近年来国内外具有代表性的文献,对药物肠淋巴转运的研究进展及研究药物肠淋巴转运的动物模型进行分析、归纳和总结。结果与讨论药物肠淋巴转运可以避免肝首过代谢增加药物的生物利用度,同时还具有淋巴靶向作用,对于具有强首过代谢的药物肠淋巴转运具有重要的意义。笔者将从药物淋巴转运的机制,药物转运和脂质吸收的关系,增加药物肠淋巴转运的方法,研究淋巴转运的动物模型等方面进行综述。
OBJECTIVE Available information on the background of the current state and advances of the intestinal lymph trans- port of medicines were reviewed. Drug transported by the intestinal lymphatic system can avoid hepatic first-pass metabolism, increase the bioavalibithy of the highly lipophilic drug, and it is of importance for immunomodulatory, anticancer and anti-infective drugs. METHODS We conducted a systematic literature review of articles published recent years, analysis and summaries are made upon the advances and methods applied for the increase of the intestinal lymph transport. RESULTS AND CONCLUSION Intestinal lym- phatic transport can increase the bioavailability via a reduction in the first-pass metabolism and the possibility of specifically targeting drugs to regions of the lymphatics, thus it is very advantageous for drugs that are under significant first-pass metabolism. The present review embodies a brief background of the mechanism of access of drugs to the intestinal lymph, a discussion on the links between lipid absorption and transport of highly lipophilic drugs, and approaches for enhancing lymphatic drug transport. Finally, experimental mod- els of the lymphatic transport are also discussed.
出处
《中国药学杂志》
CAS
CSCD
北大核心
2013年第17期1433-1438,共6页
Chinese Pharmaceutical Journal
关键词
淋巴转运
药物吸收
脂质
首过代谢
lymphatic transport
drug absorption
lipids
first-pass metabolism
